Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group

N Murphy, C Confavreux, J Haas, N König, E Roullet, M Sailer, M Swash, C Young, J L Mérot, N Murphy, C Confavreux, J Haas, N König, E Roullet, M Sailer, M Swash, C Young, J L Mérot

Abstract

Objective: To assess the quality of life (QoL) of patients with multiple sclerosis in France, Germany, and the United Kingdom with a cross sectional study.

Methods: Patients were classified into three severity groups according to the expanded disability severity scale (EDSS); stage I, II, and III, corresponding to mild (EDSS 1.0-3.5), moderate (EDSS 4.0-6.0), or severe (EDSS 6.5-8.0) multiple sclerosis respectively. Ninety patients with multiple sclerosis and 30 control patients without multiple sclerosis were recruited in each country. Control patients were matched to the patients with multiple sclerosis according to age and sex. Quality of life was assessed using the functional status questionnaire (FSQ).

Results: The aspects of QoL that were mostly affected in the three countries under study were physical function and general wellbeing. Social role function decreased with increased severity of disease in France and in particular in Germany. Multiple sclerosis did not seem to have an impact on psychological function. The QoL of control patients was systematically higher than that of patients with multiple sclerosis.

Conclusions: Use of such a generic scale showed that progression of multiple sclerosis is accompanied by a decrease in QoL and suggested that this could be a relevant measurement in assessing the effect of treatment and progression of disease. Variation between countries, however, may be important.

References

    1. Br J Cancer. 1988 Jan;57(1):109-12
    1. J Chronic Dis. 1975 Apr;28(4):199-216
    1. Ann Neurol. 1983 Mar;13(3):227-31
    1. J Health Econ. 1986 Mar;5(1):1-30
    1. J Gen Intern Med. 1986 May-Jun;1(3):143-9
    1. BMJ. 1997 May 31;314(7094):1580-3
    1. Neurology. 1991 May;41(5):692-6
    1. Arch Neurol. 1992 Dec;49(12):1237-42
    1. Ann Emerg Med. 1994 Apr;23(4):807-12
    1. Neurol Clin. 1995 Feb;13(1):197-223
    1. Qual Life Res. 1996 Oct;5(5):496-502

Source: PubMed

Подписаться